The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
 
Sophie Cousin
No Relationships to Disclose
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Andrea Fülöp
Research Funding - AstraZeneca; Janssen; MSD
 
Ildiko Horvath
Honoraria - Chiesi; Roche
Consulting or Advisory Role - AstraZeneca; Chiesi
Travel, Accommodations, Expenses - Roche
 
Jose Manuel Manuel Trigo Perez
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Takeda
Speakers' Bureau - AstraZeneca; Merck Serono; MSD Oncology; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb Foundation; MSD Oncology
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Roche/Genentech
 
Laura Bonanno
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; Novartis/Ipsen
 
Jose Antonio Lopez-Vilariño
Employment - PharmaMar
 
Carmen Maria Kahatt
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Cristian Marcelo Fernandez
Employment - PharmaMar
 
Javier Gomez
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
Patents, Royalties, Other Intellectual Property - Lurbinectedin. PharmaMar
 
Ali Hassan Zeaiter
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Alejandro Navarro
No Relationships to Disclose
 
Kostas N. Syrigos
Honoraria - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Egbert Smit
No Relationships to Disclose
 
Tudor-Eliade Ciuleanu
No Relationships to Disclose
 
Alberto Chiappori
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Abbvie; Ailleron; G1 Therapeutics; Jazz Pharmaceuticals; Merus; Sanofi/Regeneron
Speakers' Bureau - Amgen; Blueprint Medicines; Genentech; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - Amgen; Takeda
 
Rafael Lopez-Lopez
No Relationships to Disclose
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)